Keywords : stem cell, cell transplantation, stem cell transplantation, Rituximab, G-CSF, filgrastim, Umbilical cord blood, GM-CSF, T lymphocyte, Alemtuzumab, blood stem cell, umbilical cord blood transplant, cytokine, Peripheral blood stem cell transplantation, NK cell
Hodgkin Lymphoma – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Hodgkin Lymphoma - Pipeline Review, H2 2012', provides an overview of the Hodgkin Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
Hodgkin Lymphoma – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Hodgkin Lymphoma - Pipeline Review, H2 2012', provides an overview of the Hodgkin Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma. 'Hodgkin Lymphoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Hodgkin Lymphoma.
- A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hodgkin Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Hodgkin Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Biological Therapy Industry in the United States
Table of Contents
Table of Contents 2
List of Tables 9
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Hodgkin Lymphoma Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Hodgkin Lymphoma 13
Hodgkin Lymphoma Therapeutics under Development by Companies 15
Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 23
Comparative Analysis 23
Mid Clinical Stage Products 24
Comparative Analysis 24
Early Clinical Stage Products 25
Comparative Analysis 25
Hodgkin Lymphoma Therapeutics – Products under Development by Companies 26
Hodgkin Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 28
Companies Involved in Hodgkin Lymphoma Therapeutics Development 39
Seattle Genetics, Inc. 39
Merck & Co., Inc. 40
Gamida Cell Ltd. 41
Plexxikon Inc. 42
Novartis AG 43
Ono Pharmaceutical Co., Ltd. 44
4SC AG 45
Hana Biosciences, Inc. 46
AEterna Zentaris Inc. 47
MethylGene Inc 48
Allos Therapeutics, Inc 49
Cytokinetics, Inc 50
Pharmacyclics, Inc. 51
Affimed Therapeutics AG 52
Philogen S.p.A. 53
Syndax Pharmaceuticals, Inc. 54
Xencor, Inc. 55
TaiGen Biotechnology Co., Ltd. 56
Hodgkin Lymphoma – Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 64
StemEx - Drug Profile 64
SNDX 275 - Drug Profile 66
Adcetris - Drug Profile 68
Mocetinostat - Drug Profile 71
Alocrest - Drug Profile 73
PCI-24781 - Drug Profile 74
LBH589 - Drug Profile 76
Afinitor - Drug Profile 79
HCD122 - Drug Profile 82
4SC-201 - Drug Profile 84
Ispinesib - Drug Profile 86
SB-743921 - Drug Profile 88
Folotyn - Drug Profile 90
AFM13 - Drug Profile 93
XmAb2513 - Drug Profile 95
Perifosine + Sorafenib - Drug Profile 96
NiCord - Drug Profile 97
Busulfan + Melphalan + Peripheral Blood Progenitor Cell Transplantation - Drug Profile 98
Sorafenib + Everolimus - Drug Profile 99
Velcade + Ifosamide + Carboplatin + Etoposide + Mesna - Drug Profile 100
Ciclopirox Olamine - Drug Profile 102
Bexxar - Drug Profile 103
Velcade + ICE - Drug Profile 104
Clofarabine + Melphalan + Alemtuzumab + Stem Cell Transplantation - Drug Profile 106
Clioquinol - Drug Profile 108
Velcade + Dexamethasone - Drug Profile 109
Fludarabine + Busulfan + Anti-Thymocyte Globulin + Stem Cell Transplantation - Drug Profile 110
Rituximab + ABVD - Drug Profile 111
Oncaspar + Doxil + Decadron - Drug Profile 113
Avastin + Adriamycin + Bleomycin + Vinblastine + Dacarbazine - Drug Profile 115
Adriamycin + Bleomycin + Vincristine + Dacarbazine + Radiation Therapy - Drug Profile 117
NK-Cell - Drug Profile 119
Cytarabine + Cisplatin - Drug Profile 121
LBH589 + RAD001 - Drug Profile 122
Autologous LMP1 + LMP2 Specific Cytotoxic T-Lymphocytes + Anti-CD45 Monoclonal Antibody - Drug Profile 126
Cyclophosphamide + Radiation Therapy + Peripheral Stem Cell Transplantation - Drug Profile 128
Cytokine Induced Killer Cells - Drug Profile 129
Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes - Drug Profile 131
Therapeutic Allogeneic Lymphocytes - Drug Profile 132
LMP2a-Specific Cytotoxic T-Lymphocytes - Drug Profile 133
PLX 3397 - Drug Profile 134
Daclizumab + Aldesleukin - Drug Profile 136
Lenalidomide - Drug Profile 138
Folotyn + Gemcitabine Hydrochloride - Drug Profile 139
SGN-35 + Rifampin - Drug Profile 140
SGN-35 + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin - Drug Profile 142
SGN-35 + Ketoconazole - Drug Profile 144
TG-0054 - Drug Profile 145
SCH 900776 + Gemcitabine - Drug Profile 147
Vorinostat + Niacinamide + Etoposide - Drug Profile 150
Rituximab + Gemcitabine + Navelbine - Drug Profile 151
VNP40101M + Fludarabine + Hematopoietic Cell Transplantation - Drug Profile 152
Clofarabine + Busulfan + Stem Cell Transplantation + Radiation Therapy - Drug Profile 155
Galiximab - Drug Profile 159
Bleomycin Sulfate + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine - Drug Profile 162
Doxorubicin + Vinblastine + Gemcitabine - Drug Profile 174
SCH 900776 - Drug Profile 178
Adriamycin + Bleomycin + Vinblastine + Dacarbazine - Drug Profile 182
AMD3100 + G-CSF - Drug Profile 186
AMD3100 + G-CSF - Drug Profile 187
ONO-4538 - Drug Profile 188
Yttrium-90 Radiolabeled Daclizumab + Calcium-DTPA - Drug Profile 190
Treosulfan - Drug Profile 194
Rituximab - Drug Profile 195
Rituximab - Drug Profile 196
Gemcitabine + Dexamethasone + Cisplatin - Drug Profile 197
Vorinostat - Drug Profile 201
RAD001 + Revlimid - Drug Profile 202
Campath + EPOCH-R - Drug Profile 207
EPOCH FR + Tacrolimus + Methotrexate + Sirolimus + Stem Cell Transplantation - Drug Profile 209
Methotrexate + Sirolimus + Tacrolimus - Drug Profile 213
EPOCH FR + Alemtuzumab + Cyclosporine + Stem Cell Transplantation - Drug Profile 216
MSSM/BIIR HDC Vax-001 + Allogenic Stem Cell Transplantation - Drug Profile 219
G-CSF + Cyclophosphamide + Etoposide + Lomustine + Procarbazine + Radiation Therapy - Drug Profile 221
Prednisone + Vincristine + Doxorubicin Hydrochloride + Etoposide - Drug Profile 223
Busulfan + Cyclophosphamide + Etoposide + Radiation Therapy + Bone Marrow Transplantation - Drug Profile 225
Prednisone + Vincristine + Doxorubicin Hydrochloride + Etoposide + Dacarbazine + Cyclophosphamide - Drug Profile 230
Carboplatin + Cyclophosphamide + Etoposide + Stem Cell Transplantation - Drug Profile 241
Mesenchymal Stem Cells + Allogeneic Hematopoietic Stem Cells + Fludarabine + Radiation Therapy - Drug Profile 243
Fludarabine + Melphalan + Tacrolimus + Methotrexate + Stem Cell Transplantation - Drug Profile 246
Cyclophosphamide + Etoposide + Allogeneic Bone Marrow Transplantation + Radiation Therapy - Drug Profile 248
Fludarabine + Melphalan + Allogeneic Stem Cell Transplantation + Campath 1H - Drug Profile 250
ABVD Regimen + Carmustine + Etoposide + Cyclophosphamide + Stem Cell Transplantation - Drug Profile 252
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 255
Velcade + Ifosfamide + Vinorelbine + G-CSF - Drug Profile 259
Pralatrexate - Drug Profile 261
Cyclophosphamide + Fludarabine + Cyclosporine + Campath-1H + GM-CSF - Drug Profile 264
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 266
Nelfinavir + Bortezomib - Drug Profile 268
EPOCH FR + Mesna + Tacrolimus + Sirolimus + Umbilical Cord Blood Transplantation - Drug Profile 269
Stanford V Chemotherapy + Radiation Therapy - Drug Profile 272
Bleomycin + Etoposide + Doxorubicin + Cyclophosphamide + Vincristine + Procarbazine + Prednisone - Drug Profile 288
Ofatumumab - Drug Profile 290
Busulfex + Fludarabine + Allogeneic Hematopoietic Progenitor Cell Transplantation - Drug Profile 291
Ofatumumab + ESHAP Therapy + Autologous Stem Cell Transplantation - Drug Profile 293
Autologous CAR.CD30 EBV Specific-Cytotoxic T-Lymphocytes - Drug Profile 295
Doxorubicin Hydrochloride + Gemcitabine Hydrochloride + Vinblastine - Drug Profile 296
Vincristine + VP-16 + Rituximab + Dexamethasone + Levofloxacin - Drug Profile 298
Filgrastim + Busulfan + Melphalan + Thiotepa - Drug Profile 300
Filgrastim + Busulfan + Melphalan + Thiotepa - Drug Profile 301
Filgrastim + Rituximab + Cyclophosphamide - Drug Profile 302
Filgrastim + Rituximab + Cyclophosphamide - Drug Profile 304
Therapeutic Tumor Infiltrating Lymphocytes - Drug Profile 311
Therapeutic Tumor Infiltrating Lymphocytes - Drug Profile 313
Hodgkin's Antigens-GM-CSF-Expressing Cell Vaccine + G-CSF + Rituximab + Cyclophosphamide - Drug Profile 315
Allogeneic Stem Cell Transplantation - Drug Profile 319
Gemcitabine + Carboplatin + Dexamethasone + Rituximab - Drug Profile 321
Ifosfamide + Amsacrine + Etoposide - Drug Profile 323
Vincristine + Etoposide + Cyclophosphamide + Vinblastine + Prednisone + Doxorubicin Hydrochloride - Drug Profile 324
Carboplatin + Etoposide + Ifosfamide + Radiation Therapy + Autologous Stem Cell Transplantation - Drug Profile 328
Carmustine + Cyclophosphamide + Etoposide + G-CSF + Stem Cell Transplantation - Drug Profile 329
Gemcitabine + Fludarabine + Melphalan + Antithymocyte Globulin + Stem Cell Transplantation - Drug Profile 331
Gemcitabine + Busulfan + Melphalan + Dexamethasone + Palifermin + Stem Cell Transplantation - Drug Profile 334
Doxorubicin + DTIC + Revlimid + Vinblastine - Drug Profile 336
Thiotepa + Clofarabine + Busulfan + Thymoglobulin + G-CSF + Stem Cell Transplantation - Drug Profile 338
Cisplatin - Drug Profile 346
Cyclophosphamide + Peripheral Blood Stem Cell Transplantation + Radiation Therapy - Drug Profile 353
Carboplatin + Etoposide + Thiotepa + Stem Cell Transplantation + Filgrastim - Drug Profile 360
Carmustine + Cyclophosphamide + Etoposide + Stem cell Transplantation + G-CSF - Drug Profile 362
BEACOPPesc + Goserelin - Drug Profile 381
R-ABVD Regimen - Drug Profile 383
Romidepsin - Drug Profile 385
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 386
Bortezomib + IGEV - Drug Profile 394
Gemcitabine Hydrochloride + Pegylated Liposomal Doxorubicin Hydrochloride + Vinorelbine Ditartrate - Drug Profile 396
Vincristine + Prednisolone + Etoposide + Doxorubicin - Drug Profile 400
Vincristine + Prednisolone + Etoposide + Doxorubicin + Cyclophosphamide + Procarbazine - Drug Profile 402
Adriamycin + Vinblastine + Vincristine + Bleomycin + Etoposide + Cyclophosphamide + Prednisone - Drug Profile 405
ABVD + BEACOPP Regimen + Filgrastim - Drug Profile 412
Bleomycin + Rituximab + Dacarbazine + Doxorubicin + Vinblastine - Drug Profile 416
Cisplatin - Drug Profile 418
Cytarabine - Drug Profile 420
ABVD - Drug Profile 421
Lenalidomide + Bendamustine - Drug Profile 423
Lenalidomide - Drug Profile 424
Lenalidomide + Temsirolimus - Drug Profile 425
Lenalidomide + Vorinostat - Drug Profile 426
Lenalidomide + Vorinostat - Drug Profile 428
Etoposide + Ifosfamide + Cisplatin - Drug Profile 433
Etoposide + Lomustine - Drug Profile 434
Tenarad - Drug Profile 435
LMP400 - Drug Profile 436
LMP776 - Drug Profile 437
BEACOPP + Radiotherapy - Drug Profile 438
Cyclophosphamide - Drug Profile 441
Panobinostat + Cytarabine - Drug Profile 445
Etoposide + Methylprednisolone + Cytarabine + Oxaliplatin - Drug Profile 448
TAA CTL - Drug Profile 450
IGEV + Autologous Stem Cell Transplantation - Drug Profile 451
Daclizumab + Aldesleukin - Drug Profile 452
Fludarabine + Melphalan + Radiation Therapy + Umbilical Cord Blood Transplantation - Drug Profile 454
Hodgkin Lymphoma Therapeutics – Drug Profile Updates 455
Hodgkin Lymphoma Therapeutics – Discontinued Products 494
Hodgkin Lymphoma Therapeutics - Dormant Products 496
Hodgkin Lymphoma – Product Development Milestones 504
Featured News & Press Releases 504
Appendix 517
Methodology 517
Coverage 517
Secondary Research 517
Primary Research 517
Expert Panel Validation 517
Contact Us 518
Disclaimer 518
List of Tables
Number of Products Under Development for Hodgkin Lymphoma, H2 2012 27
Products under Development for Hodgkin Lymphoma – Comparative Analysis, H2 2012 28
Number of Products under Development by Companies, H2 2012 30
Number of Products under Development by Companies, H2 2012 (Contd..1) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 36
Comparative Analysis by Late Stage Development, H2 2012 37
Comparative Analysis by Mid Clinical Stage Development, H2 2012 38
Comparative Analysis by Early Clinical Stage Development, H2 2012 39
Products under Development by Companies, H2 2012 40
Products under Development by Companies, H2 2012 (Contd..1) 41
Products under Investigation by Universities/Institutes, H2 2012 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 45
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 46
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 47
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 48
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 49
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 52
Seattle Genetics, Inc., H2 2012 53
Merck & Co., Inc., H2 2012 54
Gamida Cell Ltd., H2 2012 55
Plexxikon Inc., H2 2012 56
Novartis AG, H2 2012 57
Ono Pharmaceutical Co., Ltd., H2 2012 58
4SC AG, H2 2012 59
Hana Biosciences, Inc., H2 2012 60
AEterna Zentaris Inc., H2 2012 61
MethylGene Inc, H2 2012 62
Allos Therapeutics, Inc, H2 2012 63
Cytokinetics, Inc, H2 2012 64
Pharmacyclics, Inc., H2 2012 65
Affimed Therapeutics AG, H2 2012 66
Philogen S.p.A., H2 2012 67
Syndax Pharmaceuticals, Inc., H2 2012 68
Xencor, Inc., H2 2012 69
TaiGen Biotechnology Co., Ltd., H2 2012 70
Assessment by Monotherapy Products, H2 2012 71
Assessment by Combination Products, H2 2012 72
Assessment by Stage and Route of Administration, H2 2012 74
Assessment by Stage and Molecule Type, H2 2012 77
Hodgkin Lymphoma Therapeutics – Drug Profile Updates 469
Hodgkin Lymphoma Therapeutics – Discontinued Products 508
Hodgkin Lymphoma Therapeutics – Discontinued Products (Contd..1) 509
Hodgkin Lymphoma Therapeutics – Dormant Products 510
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..1) 511
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..2) 512
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..3) 513
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..4) 514
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..5) 515
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..6) 516
Hodgkin Lymphoma Therapeutics – Dormant Products (Contd..7) 517
List of Figures
Number of Products under Development for Hodgkin Lymphoma, H2 2012 27
Products under Development for Hodgkin Lymphoma – Comparative Analysis, H2 2012 28
Products under Development by Companies, H2 2012 29
Products under Investigation by Universities/Institutes, H2 2012 32
Late Stage Products, H2 2012 37
Mid Clinical Stage Products, H2 2012 38
Early Clinical Stage Products, H2 2012 39
Assessment by Monotherapy Products, H2 2012 71
Assessment by Combination Products, H2 2012 72
Assessment by Route of Administration, H2 2012 73
Assessment by Stage and Route of Administration, H2 2012 74
Assessment by Molecule Type, H2 2012 75
Assessment by Stage and Molecule Type, H2 2012 76
